<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705298</url>
  </required_header>
  <id_info>
    <org_study_id>H19-01935</org_study_id>
    <nct_id>NCT04705298</nct_id>
  </id_info>
  <brief_title>Role of the Gut Microbiota in Pediatric Epilepsy</brief_title>
  <acronym>EPBiome</acronym>
  <official_title>Leveraging the Gut Microbiota in Pediatric Refractory Epilepsy: Safety and Feasibility of Oligofructose-enriched Inulin Supplementation for Dysbiosis and Seizure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nearly a third of children with epilepsy are refractory to pharmacotherapy. The ketogenic&#xD;
      diet (KD) is a highly effective alternative therapy reducing seizure frequency by 50% in more&#xD;
      than half of treated children. The exact mechanisms of KD remain poorly understood, and&#xD;
      recent studies have implicated the gut microbiota (GM). This pilot study aims to determine&#xD;
      the feasibility of a 12-week dietary intervention with prebiotic fiber in children with&#xD;
      epilepsy. The investigators hypothesize that consumption of inulin will alter gut microbiota&#xD;
      and may have effects on seizure frequency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in alpha and beta bacterial diversity measures in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare the effect of oral inulin vs. placebo on alpha and beta bacterial diversity in the stool of children undergoing ketogenic diet therapy for epilepsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Short Chain Fatty Acid (SCFA) levels in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare the effect of inulin vs. placebo on SCFA levels in the stool of children undergoing ketogenic diet therapy for epilepsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>12 weeks</time_frame>
    <description>Trends in seizure frequency during inulin treatment compared to pre-treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Drug Resistant Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for &gt;6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oligofructose-enriched inulin 4 grams daily for ≤ age 6; or 8 grams daily for &gt;6 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <description>Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for &gt;6 years</description>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for &gt;6 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               -  Children with epilepsy:&#xD;
&#xD;
                    1. Age 2-18.&#xD;
&#xD;
                    2. Attended the epilepsy clinic for a minimum of 6 months.&#xD;
&#xD;
                    3. Have at least 4 seizures per month at baseline.&#xD;
&#xD;
                    4. On a stable number and type of medications for 4 weeks.&#xD;
&#xD;
                    5. Have not previously been on the ketogenic diet.&#xD;
&#xD;
               -  Healthy controls:&#xD;
&#xD;
                    1. Aged 2-18.&#xD;
&#xD;
                    2. Immunocompetent.&#xD;
&#xD;
                    3. No medical comorbidities (e.g. autoimmune, metabolic, cardiovascular, renal,&#xD;
                       or gastrointestinal conditions).&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               1. Health conditions such as disorders of fatty acid transport and oxidation,&#xD;
                  porphyria, and pancreatitis, Glucose transporter 1 deficiency, pyruvate&#xD;
                  dehydrogenase deficiency, diabetes, and other autoimmune diseases.&#xD;
&#xD;
               2. Presence of HIV infection, chronic wound infection, or osteomyelitis&#xD;
&#xD;
               3. Presence of or treatment for periodontal infection&#xD;
&#xD;
               4. Inflammatory bowel disease, chronic diarrhea, current Clostridium difficile&#xD;
                  infection&#xD;
&#xD;
               5. Treatment with immunosuppressive agents in the past 6 months&#xD;
&#xD;
               6. Significant changes in dietary intake (i.e. excluded sugar, lactose or gluten&#xD;
                  from their diet, started consuming a vegetarian or vegan diet) over the past 6&#xD;
                  months.&#xD;
&#xD;
               7. Gastrointestinal illness in the past month or food intolerances leading to&#xD;
                  gastrointestinal symptoms.&#xD;
&#xD;
               8. Use of antibiotics in the 3 months preceding the study.&#xD;
&#xD;
               9. Use of probiotic or prebiotic supplements in the month preceding the study.&#xD;
&#xD;
              10. Consumption of probiotic yoghurt in the past 2 weeks.&#xD;
&#xD;
              11. Use of laxatives, proton pump inhibitors, or gastric motility medications in the&#xD;
                  month preceding the study.&#xD;
&#xD;
              12. History of allergic reaction or intolerance of maltodextrin or inulin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maksim Parfyonov, MD</last_name>
    <phone>7788635905</phone>
    <email>info@epbiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Huh, MD</last_name>
    <email>lhuh@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Pablo Appendino, MD</last_name>
      <email>JP.Appendino@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Parfyonov, MD</last_name>
      <email>info@epbiome.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British Columbia Children's Hospital</investigator_affiliation>
    <investigator_full_name>Maksim Parfyonov</investigator_full_name>
    <investigator_title>Resident, Division of Neurology</investigator_title>
  </responsible_party>
  <keyword>Ketogenic Diet</keyword>
  <keyword>Gut Microbiome</keyword>
  <keyword>Inulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

